MARKETSnap
  • Market Snapshots
    • Gainers & Losers
    • Most Active & More
    • 52-Week High/Low
    • Dividends
    • P/E Ratios
      • Large Caps
      • Absolute
      • Total Market PE
    • Stocks Performance
      • Large Caps
      • Absolute
    • Industries Performance
      • Industry
      • Sector
  • Analyze Stock
    • Analyze a stockAnalyze OPRX →
    • FindStock Picks / Stock Screener
    • Value · OPRXIntrinsic Value Calculator
    • Invest · OPRXInvestment Case
    • Hold · OPRX5-Year Outlook
  • Learn
  • Calendar
  • Investment Compounding
    Calculator
  • Investing Philosophy
  • More
    • Charts
    • Commodities
    • Currencies
    • Economic Indicators
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
OPRX stock logo

OPRX

OptimizeRx Corp.

$7.34
-1.53
 (-17.25%)
Exchange:  NASDAQ
Market Cap:  138.256M
Shares Outstanding:  18.555M
Delayed data
Overview
Earnings
Financials
Valuation
Chart

About The Company

Sector:  HealthcareView sector performance
Industry:  Medical – Healthcare Information ServicesView industry performance
   
CEO:  Stephen L. Silvestro
Full Time Employees:  133
Address: 
260 Charles Street
Waltham
MA
2453
US
Website:  https://www.optimizerx.com
OptimizeRx Corp. is digital health company, engaged in the provision of digital health messaging via electronic health records, which serve as a direct channel for pharmaceutical companies to communicate with healthcare providers. It offers electronic health record (EHR) workflow solutions which include financial messaging, patient education, and brand messaging and brand support. The company was founded by David A. Harrell in 2006 and is headquartered in Waltham, MA.

Click to read more…

Revenue Segmentation

Revenue by type

Log in to continue

Log in to see the complete revenue and geographic breakdown.

Log in — it's free

Industry Peers

TICKERCOMPANYMKT CAPP/EFWD P/EROIC
OPOPRX logoOPRXOptimizeRx Corp.138.3M27.89.04.7%
DHDH logoDHDefinitive Healthcare Corp.140.4M—6.641.9%
HCHCAT logoHCATHealth Catalyst, Inc.115.0M——-34.2%
LFLFMD logoLFMDLifeMD, Inc.105.9M——-410.1%
CCCCLD logoCCLDCareCloud, Inc.103.0M18.615.118.4%
SPSPOK logoSPOKSpok Holdings, Inc.243.8M13.017.78.9%

EPS

Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.

Log in to continue

Log in for the full EPS chart and links to analyst estimates.

Log in — it's free
View full analyst estimates

Earnings Call

Full text

Earnings transcript

Read the complete earnings call transcript.

AI summary

Key takeaways

Short, structured highlights from the call so you can focus on what matters.

2026/05/12 — Q1 quarter 2026

Log in to continue

Log in to read the full transcript and AI-generated earnings summaries.

Log in — it's free
Income Statement
Balance Sheet
Cash Flow Statement
Analyst Estimates

Income Statement

Year202320242025
Revenue71,52292,127109,429
Gross Profit42,90059,37869,268
EBITDA-21,308-8,89616,571
Operating Income-26,402-13,70612,061
Net Income-17,566-20,1105,132

Log in to continue

Log in to see the income statement and 10 historical years.

Log in — it's free

(* All numbers are in thousands)

Balance Sheet

Year202320242025
Total Assets183,373.898171,168176,918
Total Liabilities56,820.72454,17048,624
Total Stockholders Equity126,553.174116,998128,294
Total Debt36,823.80033,19326,103
Cash and Cash Equivalents13,852.45613,38023,365

Log in to continue

Log in to see the balance sheet and 10 historical years.

Log in — it's free

(* All numbers are in thousands)

Cash Flow Statement

Year202320242025
Operating Cash Flow-7,239.1534,88918,715
Capital Expenditure-871.422-112-58
Free Cash Flow-8,110.5754,77718,657
Net Income-17,565.866-20,1105,132
Net Change in Cash-4,356.229-4729,985

Log in to continue

Log in to see the cash flow statement and 10 historical years.

Log in — it's free

(* All numbers are in thousands)

Analyst Estimates

Fiscal Year2028Research AccessResearch AccessResearch AccessResearch Access
Estimated Revenue (Low)96,838.400Research AccessResearch AccessResearch AccessResearch Access
Estimated Revenue (High)105,770.938Research AccessResearch AccessResearch AccessResearch Access
Estimated Revenue (Avg)100,300Research AccessResearch AccessResearch AccessResearch Access
Estimated Ebitda (Low)27,827.515Research AccessResearch AccessResearch AccessResearch Access
Estimated Ebitda (High)30,380.854Research AccessResearch AccessResearch AccessResearch Access
Estimated Ebitda (Avg)30,046.056Research AccessResearch AccessResearch AccessResearch Access
Estimated Net Income (Low)18,690.498Research AccessResearch AccessResearch AccessResearch Access
Estimated Net Income (High)20,956.065Research AccessResearch AccessResearch AccessResearch Access
Estimated Net Income (Avg)20,659Research AccessResearch AccessResearch AccessResearch Access
Estimated SGA Expense (Low)63,241.300Research AccessResearch AccessResearch AccessResearch Access
Estimated SGA Expense (High)69,074.785Research AccessResearch AccessResearch AccessResearch Access
Estimated SGA Expense (Avg)65,501.933Research AccessResearch AccessResearch AccessResearch Access
Estimated EPS (Avg)1.030Research AccessResearch AccessResearch AccessResearch Access
Estimated EPS (High)1.100Research AccessResearch AccessResearch AccessResearch Access
Estimated EPS (Low)0.980Research AccessResearch AccessResearch AccessResearch Access
Number of Analysts (Estimated Revenue)1Research AccessResearch AccessResearch AccessResearch Access
Number of Analysts (Estimated EPS)1Research AccessResearch AccessResearch AccessResearch Access

Log in to continue

Log in with Research Access to see up to 5 years of analyst estimates.

Create a free account

(* All numbers are in thousands)

Current Key Metrics

?Revenue
 (TTM)
: 
92.127M  ?P/S
 (TTM)
: 
1.47
?Net Income
 (TTM)
: 
-20.11M  ?P/E
 (TTM)
: 
27.85
?Enterprise Value
 (TTM)
: 
129.077M  ?EV/FCF
 (TTM)
: 
6.49
?Dividend Yield
 (TTM)
: 
0%  ?Payout Ratio
 (TTM)
: 
0%
?ROE
 (TTM)
: 
3.84%  ?ROIC
 (TTM)
: 
4.71%
?Net Debt
 (TTM)
: 
19.813M  ?Debt/Equity
 (TTM)
: 
0.1
?P/B
 (TTM)
: 
1.03  ?Current Ratio
 (TTM)
: 
5.06

Log in to continue

Log in to see all key valuation metrics and ratios for this symbol.

Log in — it's free

Forward P/E Ratios

?

Forward P/E (Avg EPS estimate) — log in with Research Access for high/low estimates and the interactive table.

Forward P/E 1YResearch AccessResearch AccessResearch AccessResearch Access
8.95Research AccessResearch AccessResearch AccessResearch Access

Log in to continue

Log in with Research Access for forward P/E high/low estimates and the full multi-year table.

Create a free account

SWOT Analysis

🔒 You are currently logged out

Login

It's free

At what price to buy it? -
Intrinsic Value Calculator

Based on current fundamentals and analyst forecasts, MarketSnap estimates OPRX intrinsic value between $12.63 – $16.71 per share. This depends on revenue growth, margins, and discount rate.

This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.


Calculate OPRX Intrinsic Value

Common questions about OPRX valuation

Is OptimizeRx Corp. (OPRX) overvalued or undervalued right now?

MarketSnap estimates intrinsic value for OptimizeRx Corp. (OPRX) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.

Is OPRX a buy, hold, or sell for long-term investors?

MarketSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether OPRX trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.

What is OPRX’s P/E ratio?

You can see OPRX’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.

How is intrinsic value calculated for OPRX?

MarketSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MarketSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.

Is OPRX a good long-term investment?

Whether OPRX fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MarketSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.

Research tools for OptimizeRx Corp.

  • OptimizeRx Corp. intrinsic value calculatorEstimate what the business is worth
  • OptimizeRx Corp. 5-year outlookWhat has to go right, and what could go wrong
OPRX

1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.

Daily snapshot

-17.25
MarketSnap

Trading Metrics:

Open: 8.43   Previous Close: 8.87
Day Low: 7.23   Day High: 8.69
Year Low: 4.54   Year High: 15.59
Price Avg 50: 8.44   Price Avg 200: 7.18
Volume: 611365   Average Volume: 205593

Log in to continue

Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.

Log in — it's free
See in Nexus

Relevant news

OptimizeRx Corporation (OPRX) Q3 2026 Earnings Call Transcript
11-11-2026 20:18
OptimizeRx Corporation (OPRX) Q3 2026 Earnings Call Transcript
What OptimizeRx (OPRX) Said on Its Q3 Earnings Call
11-11-2026 19:18
What OptimizeRx (OPRX) Said on Its Q3 Earnings Call
OptimizeRx Corp. (OPRX) Q3 Earnings and Revenues Beat Estimates
11-11-2026 18:11
OptimizeRx Corp. (OPRX) Q3 Earnings and Revenues Beat Estimates
Will OPRX's OpenPath Deal Help TTD Capture More Healthcare Ad Dollars?
23-09-2026 10:15
Will OPRX's OpenPath Deal Help TTD Capture More Healthcare Ad Dollars?
Reviewing OptimizeRx (NASDAQ:OPRX) & Aclarion (NASDAQ:ACON)
16-09-2026 01:29
Reviewing OptimizeRx (NASDAQ:OPRX) & Aclarion (NASDAQ:ACON)
OptimizeRx Q2 Earnings Call Highlights
12-08-2026 21:05
OptimizeRx Q2 Earnings Call Highlights

DISCLAIMER: The stock market data provided on this website is for informational purposes only and is not intended for trading purposes. While we strive to provide accurate and timely information, we cannot guarantee that the information is accurate at the moment it is received or that it will continue to be accurate in the future. We are not responsible for any actions taken based on the information provided on this website. Always consult with a licensed financial professional before making any investment decisions.
Terms of Service

Copyright © 2025 MarketSnap. All rights reserved.

How MarketSnap works

What’s new

Contact Us

Privacy Policy

Cookie Policy

Terms of Service

Hover Image
MARKETSnap

Market

🇺🇸 United States

Language

    • Gainers & Losers
    • Most Active & More
    • 52-Week High/Low
    • Dividends
      • Large Caps
      • Absolute
      • Total Market PE
      • Large Caps
      • Absolute
      • Industry
      • Sector
    • Analyze a stockAnalyze OPRX →
    • FindStock Picks / Stock Screener
    • Value · OPRXIntrinsic Value Calculator
    • Invest · OPRXInvestment Case
    • Hold · OPRX5-Year Outlook
  • Learn
  • Calendar
  • Investment Compounding Calculator
    • Charts
    • Commodities
    • Currencies
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
  • Investing Philosophy
  • Nexus
    • Recent Activity
      • Overview
      • My Valuations
      • My Investment Journal
      • Watchlists & Portfolio
    • Settings
    • Public profile ↗
  • Log in

Media

Watch Listen Read
Ask MarketSnap AI

MarketSnap AI Assistant

Uses MarketSnap data and this page

Ready

🔒 You are currently logged out

Login

It's free

MarketSnap Assistant · Tips
    MarketSnap

    Welcome to MarketSnap

    The AI-powered workspace for stock pickers.

    Continue with Google Continue with email

    Already a member? Sign in

    Find stocks·Value them·Build the case·Journal decisions·Track what changes

    Free to join. No card needed. Privacy Policy

    Create your free MarketSnap account Continue with Google
    Chat with us MarketSnap support · account, plans, settings, help
    How MarketSnap works

    The conversation above goes to the MarketSnap team with your message. We reply by e-mail.